Canada NewsWire
CALGARY, Dec. 13, 2016
CALGARY, Dec. 13, 2016 /CNW/ - Resverlogix Corp.
("Resverlogix" or the "Company") (TSX:RVX) announced today that it has filed its unaudited interim Consolidated Financial
Statements and Management's Discussion & Analysis for the quarter ended October 31, 2016 and
related Management's Discussion and Analysis with Canadian securities regulatory authorities. Copies of these documents may be
obtained online at www.sedar.com, or the Company's website,
www.resverlogix.com, or by emailing ir@resverlogix.com.
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and
extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes.
Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This
selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for
patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's
disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only
selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with
type 2 DM and low high-density lipoprotein (HDL).
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
For further information please visit www.resverlogix.com.
Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on our blog at http://www.resverlogix.com/blog
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
SOURCE Resverlogix Corp.
